Bedaquiline as a potential agent in the treatment ofMycobacterium abscessusinfections
- 21 May 2017
- journal article
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 49 (5) , 1700083
Abstract
Bedaquiline may be a potential agent to treat severe or relapsing Mycobacterium abscessus infectionhttp://ow.ly/3lUp309VZVjKeywords
This publication has 15 references indexed in Scilit:
- Randomized Trial of Liposomal Amikacin for Inhalation in Nontuberculous Mycobacterial Lung DiseaseAmerican Journal of Respiratory and Critical Care Medicine, 2017
- Compassionate use of new drugs in children and adolescents with multidrug-resistant and extensively drug-resistant tuberculosis: early experiences and challengesEuropean Respiratory Journal, 2016
- Recommendations of the German Central Committee against Tuberculosis (DZK) and the German Respiratory Society (DGP) for the Diagnosis and Treatment of Non-tuberculous MycobacteriosesPneumologie, 2016
- First experience of effectiveness and safety of bedaquiline for 18 months within an optimised regimen for XDR-TBEuropean Respiratory Journal, 2016
- Bedaquiline and multidrug-resistant tuberculosis: a systematic and critical analysis of the evidenceEuropean Respiratory Journal, 2016
- Determination of MIC Distribution and Epidemiological Cutoff Values for Bedaquiline and Delamanid in Mycobacterium tuberculosis Using the MGIT 960 System Equipped with TB eXiSTAntimicrobial Agents and Chemotherapy, 2015
- Bactericidal mode of action of bedaquilineJournal of Antimicrobial Chemotherapy, 2015
- Multidrug-Resistant Tuberculosis and Culture Conversion with BedaquilineNew England Journal of Medicine, 2014
- Paediatric lung transplant outcomes vary withMycobacterium abscessuscomplex speciesEuropean Respiratory Journal, 2013
- Minimal inhibitory concentrations of first-line drugs of multidrug -resistant tuberculosis isolatesLung India, 2012